CA3202198A1 - Cocrystal of a cdk inhibitor - Google Patents

Cocrystal of a cdk inhibitor

Info

Publication number
CA3202198A1
CA3202198A1 CA3202198A CA3202198A CA3202198A1 CA 3202198 A1 CA3202198 A1 CA 3202198A1 CA 3202198 A CA3202198 A CA 3202198A CA 3202198 A CA3202198 A CA 3202198A CA 3202198 A1 CA3202198 A1 CA 3202198A1
Authority
CA
Canada
Prior art keywords
compound
formula
fumarate
cocrystal
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3202198A
Other languages
English (en)
French (fr)
Inventor
Uday Bhat
Ranadeep Bokalial
Sangamesh Eshwarappa Badiger
Krishnaswamy DEVANATHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd
Publication of CA3202198A1 publication Critical patent/CA3202198A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3202198A 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor Pending CA3202198A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041055174 2020-12-18
IN202041055174 2020-12-18
PCT/IB2021/061895 WO2022130304A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Publications (1)

Publication Number Publication Date
CA3202198A1 true CA3202198A1 (en) 2022-06-23

Family

ID=80001496

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3202198A Pending CA3202198A1 (en) 2020-12-18 2021-12-17 Cocrystal of a cdk inhibitor

Country Status (17)

Country Link
US (1) US20240059669A1 (cg-RX-API-DMAC10.html)
EP (1) EP4263534A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023554492A (cg-RX-API-DMAC10.html)
KR (1) KR20230159363A (cg-RX-API-DMAC10.html)
CN (1) CN116685326A (cg-RX-API-DMAC10.html)
AU (1) AU2021402415A1 (cg-RX-API-DMAC10.html)
CA (1) CA3202198A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001753A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023009368A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230261A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000126A (cg-RX-API-DMAC10.html)
EC (1) ECSP23054131A (cg-RX-API-DMAC10.html)
IL (1) IL303738A (cg-RX-API-DMAC10.html)
MX (1) MX2023007218A (cg-RX-API-DMAC10.html)
PE (1) PE20231441A1 (cg-RX-API-DMAC10.html)
TW (1) TW202241881A (cg-RX-API-DMAC10.html)
WO (1) WO2022130304A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232010A4 (en) * 2020-10-22 2024-09-04 Aurigene Oncology Limited CANCER THERAPY USING A CDK7 INHIBITOR IN COMBINATION WITH AN ANTI-MICROTUBULE AGENT
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
CN118772106A (zh) * 2024-06-07 2024-10-15 山东大学 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3302448T3 (da) * 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore

Also Published As

Publication number Publication date
WO2022130304A1 (en) 2022-06-23
PE20231441A1 (es) 2023-09-14
CL2023001753A1 (es) 2024-02-02
ECSP23054131A (es) 2023-09-29
JP2023554492A (ja) 2023-12-27
TW202241881A (zh) 2022-11-01
CN116685326A (zh) 2023-09-01
AU2021402415A1 (en) 2023-07-06
CR20230261A (es) 2023-10-04
CO2023009368A2 (es) 2023-09-29
US20240059669A1 (en) 2024-02-22
DOP2023000126A (es) 2023-11-30
IL303738A (en) 2023-08-01
KR20230159363A (ko) 2023-11-21
MX2023007218A (es) 2023-07-27
EP4263534A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
US20240059669A1 (en) Cocrystal of a cdk inhibitor
JP7829523B2 (ja) 多環式tlr7/8アンタゴニスト及び免疫障害の治療におけるそれらの使用
CN115175734B (zh) 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
US20240132523A1 (en) Salts and crystalline forms of a pd-1/pd-l1 inhibitor
JP7665593B2 (ja) Pd-1/pd-l1阻害剤の塩
US10723700B2 (en) Salts of an LSD1 inhibitor
CA3115609C (en) Processes of making and crystalline forms of a mdm2 inhibitor
CN103619840B (zh) (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物
CN117203208A (zh) 靶向活化与失活态kras g12d的抑制剂
CN111971287A (zh) 作为trk激酶抑制剂的大环化合物
WO2021233133A1 (zh) 用作ret激酶抑制剂的化合物及其应用
JP2022549353A (ja) プロテインキナーゼc(pkc)に作用するジテルペノイド化合物
KR102847760B1 (ko) 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도
JP5134234B2 (ja) 異常な細胞増殖の治療用のピリミジン誘導体
EA050691B1 (ru) Сокристалл ингибитора cdk
HK40099717A (en) Cocrystal of a cdk inhibitor
CA2914854C (en) Polymorph forms of icotinib maleate and uses thereof
HK40099799A (en) Process for the preparation of biheteroaryl compounds and crystal forms thereof
HK40063935A (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
WO2020222189A1 (en) Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide
WO2020222190A1 (en) Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260617